 BOSTON, July 11, 2022 GLOBE NEWSWIRE -- Cue Biopharma, Inc. Nasdaq: CUE, a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patients body, announced today that it will take part in a fireside chat at the Guggenheim II Spotlight Series Treg-based Therapies being held July 1213, 2022. 